None listed
Conditions
Interventions
Intervention1: Somatotropin human growth hormone 4IU: Implant will be inserted by topicl application of 4IU 1.2 mg of lyophilised somatropin growth hormone in stage 1 surgery when implant will be plac
Sponsors
Dr Sonal Kumbare
Eligibility
Inclusion criteria
Inclusion criteria: ASA (American Society of Anesthesiologists) 1 patient indicates that the patient is a "normal healthy patient" with no systemic disease, a non-smoking individual, and without any significant health issues that would increase the risk of anesthesia or surgical procedures18. Patient with completely or partially edentulous arches. Patients with adequate bone volume for placement of dental implant. All women with natural menopause and no previous fractures. Patients of the age group between 18 to 60 years of age Patients willing to participate in the study by giving a written consent form ASA (American Society of Anesthesiologists) 1 patient indicates that the patient is a "normal healthy patient" with no systemic disease, a non-smoking individual, and without any significant health issues that would increase the risk of anesthesia or surgical procedures.Patient with completely or partially edentulous arches. Patients with adequate bone volume for placement of dental implant. All women with natural menopause and no previous fractures. Patients of the age group between 18 to 60 years of age Patients willing to participate in the study by giving a written consent form
Exclusion criteria
Exclusion criteria: General contraindication to dental implant treatment (uncontrolled diabetes, severe cardiovascular diseases, osteoporosis, and infectious diseases). Patients with a habit of smoking and alcohol consumption. Patients with inadequate bone volume for implant placement.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome of the Study- The primary expected outcome of the study is improved osseointegration and bone density in dental implants in patients treated with Human-recombinant Somatropin growth hormone (4 iu). Timepoint: time interval between 3 months 6 months and then 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary expected outcome of the study is enhanced bone implant contact due to the application of Humanrecombinant Somatropin growth hormone 4iu Timepoint: Radiographic analysis will be done by assessing bone density preoperatively Bone density & radiofrequency analysis will be done in 3 months & 6 months | — |
Countries
India
Contacts
Public ContactDr Vaibhav Tiwari
Government Dental College Raipur
Outcome results
None listed